DSIP
A naturally occurring neuropeptide that modulates sleep patterns and has been studied for insomnia and stress.
What is DSIP?
DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring neuropeptide first isolated in 1977 from the cerebral venous blood of rabbits during induced sleep. Despite its name, its relationship to sleep is more nuanced than simply 'inducing' it — it appears to modulate sleep architecture and stress responses rather than acting as a sedative. Multiple clinical trials in chronic insomnia patients and a pilot study in chronic pain have been conducted.
What DSIP Is Investigated For
DSIP has been investigated since the late 1970s for chronic insomnia, stress modulation, opioid and alcohol withdrawal, chronic pain, and more recently preclinical signals in stroke recovery and neuroprotection. The most direct human evidence is a cluster of 1980s clinical trials in chronic insomnia showing modulation of sleep architecture (delta waves, sleep spindles) rather than acute sedation, plus a small chronic pain pilot study and several ACTH/cortisol studies. The honest caveats are pronounced: the human trial literature is decades old, methodologically heterogeneous, and has not been replicated under modern diagnostic and polysomnographic standards; pharmaceutical development was effectively discontinued by the late 1990s; and the few persistent clinical applications (notably in opioid withdrawal via the Russian Deltaran formulation) live outside Western regulatory review. DSIP is better understood today as a multifunctional neuroendocrine modulator than as the 'sleep peptide' its name implies — genuinely interesting biology with a thin and aging evidence base.
History & Discovery
DSIP — Delta Sleep-Inducing Peptide — was identified in 1977 by Marcel Monnier and his group at the University of Zurich. Their experimental setup is now part of the lore of sleep neuroscience: by stimulating the thalamus of donor rabbits to induce a delta-wave sleep-like state and then dialyzing cerebral venous blood from those animals into freely moving recipient rabbits, the Zurich group found that the recipients would shift toward delta-rich sleep patterns. The active fraction was eventually purified and sequenced as a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu), and the synthetic peptide was named after the EEG signature it induced. The early excitement was substantial. DSIP appeared to be a candidate endogenous sleep regulator at a time when the molecular basis of sleep was largely unknown, and a flurry of clinical trials in the late 1970s and 1980s tested it in chronic insomnia, narcolepsy, opioid and alcohol withdrawal, chronic pain, and stress. Results were mixed. Some studies showed sleep-architecture effects that did not consistently translate to subjective sleep improvement; others reported notable effects on stress and pain modulation. Mechanistically, DSIP turned out to be more interesting as a multifunctional modulator of the HPA axis, opioid systems, and sleep architecture than as a 'sleep peptide' in the simple sense its name implies. By the late 1990s, mainstream pharmaceutical interest in DSIP had largely faded. Some Russian and Eastern European clinical use persisted, including for opioid withdrawal protocols. Outside that limited niche, the peptide became primarily a research tool and a research-chemical-market product, with online communities citing the original 1980s human studies long after pharmaceutical development had stopped.
How It Works
DSIP appears to work by modulating the brain's sleep-wake systems, potentially helping to normalize sleep patterns. Rather than forcing sleep like a sedative, it may help your brain's natural sleep architecture function more normally.
DSIP is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) that modulates multiple neuroendocrine systems. It affects GABA, glutamate, and serotonin systems. It has been shown to modulate cortisol and ACTH release, influence LH secretion, and affect pain perception through opioid system interactions. Its effects on sleep appear to involve modulation of sleep spindle activity and delta wave patterns.
Evidence Snapshot
Human Clinical Evidence
Emerging. Multiple double-blind clinical trials in chronic insomnia patients demonstrate sleep-modulating effects. A pilot study shows analgesic effects in chronic pain. Clinical observations link decreased DSIP levels to Cushing syndrome and sleep apnea.
Animal / Preclinical
Moderate. Preclinical data supports antinociceptive, anti-stress, and neuroprotective effects. A stroke recovery study showed motor function improvement.
Mechanistic Rationale
Moderate. Multiple pathways identified (GABA, opioid, stress-hormone modulation) but the primary mechanism remains debated.
Research Gaps & Open Questions
What the current literature has not yet settled about DSIP:
- 01Modern controlled trials in insomnia using contemporary diagnostic criteria, polysomnographic methods, and outcome measures — the existing human literature is decades old and methodologically uneven.
- 02Pharmacokinetics in humans by route — older work characterized intravenous DSIP, but subcutaneous (the route most commonly used in current research-chemical contexts) has thin published pharmacokinetic data.
- 03Long-term safety beyond short-course trials — chronic daily or near-daily use over months has not been studied.
- 04Mechanistic clarity — multiple pathways are implicated (sleep architecture, HPA axis, opioid, GABA, serotonin) but the primary driver of any therapeutic effect remains debated.
- 05Comparative efficacy versus modern sleep medicines — DSIP has not been formally compared with z-drugs, DORAs, melatonin agonists, or other contemporary sleep agents.
- 06Reproducibility of the early human findings — many of the most-cited studies have not been replicated using modern methodology.
Forms & Administration
DSIP is administered via subcutaneous or intravenous injection. Protocols should be determined by a qualified clinician.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Published clinical research has used 25–500 nmol/kg of body weight via slow intravenous infusion in some protocols, and bolus IV doses of 25 µg/kg in others. Subcutaneous research-chemical protocols described in online communities typically cite 100–500 µg per dose, but these numbers are extrapolations from the older clinical literature rather than separately validated subcutaneous dose-response data.
Frequency
Most clinical research used single doses or short courses (typically administered 30–60 minutes before sleep for sleep-architecture endpoints). The largest clinical trials in chronic insomnia used several consecutive nights of dosing. There is no validated chronic-use schedule.
Timing Considerations
Time of day
30–60 minutes before bed. DSIP's primary claimed effect is sleep-onset and sleep-architecture modulation; dosing outside the pre-sleep window makes little mechanistic sense.
Relative to meals
Avoid heavy meals in the 1–2 hours before dosing so digestion doesn't interfere with sleep onset; otherwise meal timing is not critical.
Relative to exercise
Unrelated to training.
Cycle Length
Published clinical protocols are short — days to a few weeks. Long-term continuous use has not been studied. Research-chemical-channel protocols often cite 4–6 week courses, but these have no clinical-evidence basis.
Protocol Notes
DSIP is biologically unstable. It has a very short plasma half-life (minutes), and its functional effects appear to outlast its measurable plasma presence — a pattern consistent with downstream signaling rather than sustained receptor occupancy. Practical implications: timing relative to the desired effect window matters more than maintaining steady-state levels. Route matters for interpretation of the clinical literature. Most published human work used intravenous administration in research settings; subcutaneous self-administration as practiced in research-chemical contexts is not the same exposure profile and the equivalence is not established. The sourcing problem is significant. There is no pharmaceutical-grade DSIP product on Western markets; some Eastern European pharmaceutical product (notably 'Deltaran,' a DSIP-containing formulation studied in Russian work) exists but is not widely available. Research-chemical-channel DSIP is unverified for purity, identity, and stability — and DSIP is particularly susceptible to degradation, so even authentic product can lose activity if mishandled.
DSIP is not approved for any indication in the US, EU, UK, or most major regulatory jurisdictions. The 1980s clinical literature is real but the pharmaceutical development was discontinued; current research-chemical use is not the same context as approved clinical care.
Timeline of Effects
Onset
In published intravenous infusion studies, sleep-architecture effects (changes in delta wave activity, sleep spindle patterns) were measured during and immediately after the infusion period. Subjective sleep effects, where reported, emerged within the first night of dosing. For pain and stress modulation endpoints, effects have been described within 30–60 minutes of administration.
Peak Effect
Peak central effects are typically described in the 1–3 hour window after a single dose, despite the peptide's short plasma half-life. Cumulative sleep-architecture changes in chronic-insomnia trials were generally assessed across 3–7 nights of dosing.
After Discontinuation
Acute effects fade within hours of clearance. Sleep-architecture changes documented during dosing typically did not persist as durable effects after discontinuation in the published trials, which is part of why DSIP was not pursued as a chronic insomnia therapy. No withdrawal syndrome or rebound insomnia has been described in the clinical literature.
Common Questions
Who DSIP Is NOT For
- •Pregnancy — no human pregnancy or reproductive-toxicology data; effects on the developing fetal HPA axis and CNS are uncharacterized.
- •Breastfeeding — no data on milk transfer or infant exposure.
- •Pediatric use outside specific research settings — no pediatric safety data.
- •Concurrent opioid dependence treatment under medical supervision — DSIP has been studied in some opioid withdrawal protocols, but unsupervised use alongside medically managed opioid agonist therapy (methadone, buprenorphine) is inadvisable due to unstudied interactions with the endogenous opioid system.
- •Active major depression or psychiatric instability — DSIP's effects on stress hormones and mood-related neurotransmission are not well characterized in psychiatric populations and could plausibly destabilize ongoing psychiatric care.
- •Known hypersensitivity to DSIP or to research-chemical excipients of unverified composition.
Drug & Supplement Interactions
Documented clinical drug interactions for DSIP are limited. The published clinical literature is decades old and predates the systematic interaction-study framework used today. The most plausible theoretical interactions involve other agents acting on the HPA axis and CNS sleep-regulating systems. With benzodiazepines, z-drugs (zolpidem, zopiclone, eszopiclone), and dual orexin receptor antagonists (suvorexant, lemborexant, daridorexant), DSIP's modulation of sleep architecture could be additive in unpredictable ways; co-use has not been studied. With opioids and opioid-replacement therapies, DSIP's documented effects in opioid-withdrawal protocols suggest interaction with endogenous opioid signaling, but the magnitude in the context of chronic opioid agonist therapy is not characterized. With corticosteroids and any drug that influences ACTH/cortisol dynamics, DSIP's reported effects on ACTH and AVP secretion in early human studies suggest theoretical interaction, though the clinical relevance is unclear. No documented interaction concerns exist with typical cardiovascular medications, oral hypoglycemics, or anticoagulants. As always, patients on regular medications should disclose any DSIP use to their prescriber. Absence of documented interaction reflects the age and limited scope of the human literature, not absence of risk.
Safety Profile
Common Side Effects
Cautions
- • Limited and sometimes contradictory research
- • Not FDA-approved
- • Mechanism not fully understood
What We Don't Know
The exact mechanism of action and optimal use parameters are not well established despite decades of research.
Legal Status
United States
DSIP is not FDA-approved for any indication. It is not a controlled substance, but it is also not a recognized dietary supplement ingredient and not legitimately compounded as a medication. Sale is essentially limited to research-chemical channels, which are not authorized for human use.
International
Not approved as a medicine by EMA, MHRA, TGA, or Health Canada. Some Russian and Eastern European clinical use persists in specific contexts (e.g., the Deltaran formulation), but DSIP is not a registered medicine in major Western jurisdictions. Importation through research-chemical channels is restricted in some jurisdictions and actively enforced in others (e.g., Australia's TGA).
Sports & Competition
DSIP is not currently named on the WADA Prohibited List. WADA's S0 'non-approved substances' clause arguably applies, since DSIP is not approved for human therapeutic use in major regulatory jurisdictions. Athletes subject to WADA, USADA, or equivalent bodies should treat it as prohibited absent specific guidance.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
DSIP is a sedative that puts you to sleep like a sleeping pill.
Reality
DSIP modulates sleep architecture rather than acting as a sedative-hypnotic. The clinical literature describes effects on EEG patterns and sleep-stage distribution, not consistent acute sedation. People expecting drowsiness like a benzodiazepine or z-drug are typically describing a peptide that does something more subtle and less reliable as an acute sleep-onset agent.
Myth
DSIP is well-validated for insomnia.
Reality
DSIP has been studied in clinical trials for insomnia going back to the 1980s, but the results were mixed and pharmaceutical development was discontinued. It is not a validated insomnia treatment by modern evidence-based standards. The studies that exist are decades old, methodologically heterogeneous, and have not been replicated in contemporary trials.
Myth
Because DSIP is endogenous, it is safe to use indefinitely.
Reality
Endogenous origin is not a safety property. Endogenous DSIP exists in tightly regulated, low concentrations as part of complex circadian and stress signaling. Bolus exogenous administration in non-physiologic patterns has not been studied for long-term safety, and effects on the HPA axis and opioid system raise theoretical concerns that have not been characterized over chronic use.
Myth
All DSIP products are equivalent because the molecule is well-known.
Reality
DSIP is a particularly unstable peptide and is unusually sensitive to degradation. Research-chemical product varies in purity, identity, and remaining biological activity. Without third-party analytical testing, two vials labeled 'DSIP' from different sources are not necessarily delivering the same compound at the same potency.
Myth
DSIP is FDA-approved or in active clinical development.
Reality
It is neither. Pharmaceutical development was effectively discontinued by the late 1990s. Some limited Eastern European clinical use persists for specific indications, but the compound is not in active Western clinical development as of writing.
Published Research
41 studiesDelta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke.
Phosphorylated delta sleep inducing peptide restores spatial memory and p-CREB expression by improving sleep architecture at high altitude.
An RCT study on the feasibility of anterior transpedicular screw fixation in the cervicothoracic junction
Delta sleep-inducing peptide and glucocorticoid-induced leucine zipper: potential links between circadian mechanisms and obesity?
Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia
[Endogenous anticonvulsants: neuropeptide Y and delta sleep inducing peptide]
Delta sleep-inducing peptide and Deltaran: potential approaches to antistress protection
[Delta-sleep inducing peptide and the drug deltaran: possible approaches to antistress protection]
Delta sleep-inducing peptide (DSIP): a still unresolved riddle
Antiepileptic activity of delta sleep-inducing peptide and its analogue in metaphit-provoked seizures in rats
Opioid detoxification with delta sleep-inducing peptide: results of an open clinical trial.
Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion in normal women
Plasma concentration of nine hormones and neurotransmitters during usual activities or constant bed rest for 34 H
Delta-sleep-inducing peptide does not affect CRH and meal-induced ACTH and cortisol secretion
Decreased delta-sleep and plasma delta-sleep-inducing peptide in patients with Cushing syndrome
Different effects of delta-sleep-inducing peptide on arginine-vasopressin and ACTH secretion in normal men
The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep
Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior
CSF-plasma relationships for DSIP and some other neuropeptides
Effects of DSIP in man. Multifunctional psychophysiological properties besides induction of natural sleep
Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study.
DSIP in the treatment of withdrawal syndromes from alcohol and opiates.
Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP)
A clinical trial with DSIP
DSIP in insomnia
Development of an enzyme immunoassay for delta sleep-inducing peptide (DSIP) and its use in the determination of the metabolic clearance rate of DSIP administered to dogs
Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors.
Delta-sleep-inducing peptide (DSIP): a review
Entry of DSIP peptides into dog CSF: role of physicochemical and pharmacokinetic parameters
Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia
Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs
Effects of DSIP, 5-HTP and serotonin on the lymphokine system: a preliminary study
[Delta sleep-inducing peptide in the blood and hypothalamus of rats with various resistance to emotional stress]
Delta-sleep-inducing peptide reduces CRF-induced corticosterone release.
Delta sleep inducing peptide inhibits somatostatin release via a dopaminergic mechanism
Potent antinociceptive effect of centrally administered delta-sleep-inducing peptide (DSIP).
Reduction of immunoreactive ACTH in plasma following intravenous injection of delta sleep-inducing peptide in man
Comparison of DSIP- (delta sleep-inducing peptide) and P-DSIP-like (phosphorylated) immunoreactivity in cerebrospinal fluid of patients with senile dementia of Alzheimer type, multi-infarct syndrome, communicating hydrocephalus and Parkinson's disease
[The hypnogenic effects of delta sleep-inducing peptide (DSIP) analogs: a comparative study in rabbits and rats]
Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study
The delta sleep inducing peptide (DSIP). Comparative properties of the original and synthetic nonapeptide
Quick Facts
- Class
- Neuropeptide
- Tier
- D
- Evidence
- Emerging
- Safety
- Limited Data
- Updated
- Mar 2026
- Citations
- 41PubMed
Also known as
Tags
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.